Rectal NeoplasmsNCT03516916
Surviving Rectal Cancer at the Cost of a Colostomy International Validation of the Colostomy Impact Score
An observational study of Rectal Neoplasms and Quality of Life, run by Aarhus University Hospital at 1 site in Denmark.
Trial summary
The formation of a colostomy following surgery for rectal cancer changes body image, challenges patient practical skills and threatens quality of life. As the oncological results have improved over the last decades the number of survivors from rectal cancer who have to adjust to a cancer free life in their own homes… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rectal Neoplasms, Quality of Life, Colostomy Stoma
- What is being tested?
- Questionnaires on HRQoL and sociodemography
- How many people
- 3,750 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Feb 2019to 31 Dec 2020
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients with a permanent colostomy after curative intended surgery for rectal cancer. Time since surgery must be more than 1 year. In some countries the cohort will be extracted from a national or institutional registry representing all operated patients in a certain time period that allows for inclusion of 250 patients. In countries whithout such registries convenient inclusion from the surgical department or stoma clinic.
Who may be able to join
- Curative intended Hartmann's procedure or abdominal perineal excision >12 months ago for carcinoma of the rectum
- Permanent colostomy
Who cannot join
- Age < 18 years
- Recurrence of cancer
- Mental dementia
- Unable to understand the actual language
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Department of Surgery, Aarhus University Hospital
Aarhus, Aarhus C, 8000
About this study
The formation of a colostomy following surgery for rectal cancer changes body image, challenges patient practical skills and threatens quality of life. As the oncological results have improved over the last decades the number of survivors from rectal cancer who have to adjust to a cancer free life in their own homes is increasing. To enable the identification of the patients with stoma-related reduced health-related Quality of life (HRQoL) in a quick and reliable way we recently developed the Colostomy Impact Score (CI-score) comprising 7 items of stoma related factors with significant impact on HRQoL. The purpose of the present project is to perform an international validation of the CI-score and to demonstrate its applicability.
The construct validity of the CI-score will be studied internationally on crosssectional cohorts of patients with permanent colostomy after abdominoperineal excision (APE) or Hartmann's procedure in Denmark, Sweden, Spain, the Netherlands, United Kingdom, Turkey, Brazil, Egypt, Russia, Lithuania, Israel, Portugal, South Africa, Australia and China. This will be done by testing the CI-score against five anchor questions stoma impact on HRQoL, the 5 Level version og the EuroQol measuer (EQ-5D-5L) and version 3.0 of the Quality of Life Questionnaire from the European Organisation for Research and Treatment of Cancer (EORTC QLQ C30 questionnaire v3.0).
The impact of the challenges related to having a stoma may vary with different demographic, socioeconomic and cultural factors. Supplementary data on stoma care, demographics and socioeconomic status will be gathered to study the impact of patient-related factors and cultural differences on HRQoL in rectal cancer survivors with an ostomy.
Read the detailed description
This retrospective cohort study has three main aims: 1) To identify demographic and socioeconomic factors influencing stoma impact and HRQoL, 2) To asses reliability and to validate the translated and cross-cultural adapted CI score internationally in multiple different centres, across a variety of patient groups and across cultural, religious, socioeconomic and physical borders and 3) To investigate if differences in everyday stoma care and -costs across countries and cultures affect CI or HRQoL.
International validation will be conducted as a retrospective cohort study on patients with a permanent colostomy after curative intended surgery more than 12 months prior to inclusion. Local health care professionals will identify includable patients and register relevant clinical information on each patient from the hospital chart. Most centres will include patients from national or regional databases, some will however include conveniently if a database is not available. Our international collaborators will be responsible for sending out and collecting the questionnaires and returning the completed questionnaires to the undersigned. In countries with sufficient internet accessibility and -infrastructure the data collection will be web based i.e. patients are sent a link to the redcap-database for them to enter their answers directly. Some centres will employ paper versions of the questionnaires. In areas with substantial number of illiterates investigator led interviews can be performed.
As the CI-score is a construct based on a formative model, statistical analysis based on the Classical Test Theory(CCT) and Item Response Theory (IRT) cannot be applied. However, the following aspects of validity and reliability from the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) checklist15-17 can and will be evaluated:
Content validity: Comprehensiveness and relevance of the questions in the CI-score have been ensured with the way of the development of the CI-score with the starting point in a Basic Stoma Questionnaire developed by an expert group supplemented by patients ensuring that all possible factors affecting stoma function/impact was included before regression analysis lead to the seven weighed questions1. After translation and cross-cultural adaptation face-validity of each translated CI-score will be assessed again by the collaborators before inclusion of patients.
Construct validity: This will be tested with hypothesis-testing. Hypotheses regarding mean differences and expected correlations between scores of instruments are formulated a priori. Hypotheses on how the CI-score and HRQoL are related to other factors are formulated a priori. For convergent validation the CI-score will be tested against 5 anchor questions (not validated) and the EORTC QLQ C30+ the colorectal specific CR29 (validated). Cross-cultural validity: See translation section.
Reliability: For a randomly selected subgroup in each country the CI-score and anchor question will be administered twice with an interval of approximately 2 weeks. The two administrations will be independent and both the setting when answering and the forms of administration will be similar for the individual patient. For ensuring stable patients an extra question on recent changes in stoma function will be added to the retest.
Translation of the CI-score will be managed by the lead institution with few exceptions (Turkey, Russia, Israel) and will follow the translation procedure recommended by the World Health Organization. All translations are produced by a forward-backward procedure. The latter procedure is performed to ensure, that the original meaning of the concepts is derived.
The original Danish version of the CI-score has already undergone a professional translation to English. A professional translation agency will perform the translation of the English version to languages in the included countries. All questionnaires/Case Report Forms (CRF) to be filled in by patients will undergo the same translation procedure as above.
A master version of the questionnaires will be collected into a booklet. On this basis, a RedCap database will be constructed to allow for direct electronic data entry by patients. Patient not able to access the web-based system, will fill in a paper version of the booklet. According to variation between populations in respect to practically illiterate's investigator lead data collection will be allowed. However, this should be agreed by the local investigation and the steering group in the planning of the data collection and included as individual amendment to the final protocol.
Data analysis:
Construct validity: Convergent validity will be studied by testing the CI-score on APE/Hartmann-patients against two measures of HRQoL; the anchor-questions assessing the overall stoma-impact on HRQoL, the EORTC QLQ C30 questionnaire version 3.0 and the EORTC QLQ CR29. Construct validity will furthermore be assessed by hypothesis-testing assessing the direction and magnitude of the expected correlations. Test-retest reliability will be studied on a subgroup in all included countries. Also, we will include questions on background demographics, socioeconomic status, everyday stoma care and -costs thereby enabling investigation of the practical and economic aspect of living with a stoma varying from country to country.
Statistical analysis:
Statistical analysis will be performed separately for each country. The correlations between total CI-score, anchor questions and the EORTC questionnaire results will be calculated for all participating patients according to the guidelines for the scores. For each CI-score group (minor CI/major CI) the mean EORTC QLQ C30-score will be calculated, testing the overall difference of impact on HRQoL between the CI-score groups.
Using the anchor-questions, the patients are divided into two HRQoL groups of those reporting no/minor or some/major impact on HRQoL. Relationship between CI-score and HRQoL group will be illustrated in box-plot for each country, where we expect statistically significant differences in median CI-score between the two HRQoL groups. Differences will be tested by Mann-Whitney U test. A contingency 2 by 2 table will be used to assess the degree of agreement between the two CI-score groups and the two HRQoL groups. Based on this, the sensitivity for the score will be calculated for each country. The added questions about irrigation and stoma-bag change frequency will be compared country-wise. Univariate regression analysis, descriptive analysis and estimation of impact on HRQoL will be performed. Test-retest reliability will be evaluated using Intraclass Correlation Coefficient and Cohens' Kappa.
- Conditions
- Rectal Neoplasms, Quality of Life, Colostomy Stoma
- Being tested
- Questionnaires on HRQoL and sociodemography
- Keywords
- Rectal cancer, HRQoL, Stoma, Colostomy, Patient reported outcome measure (PROM)
- Medical subject headings
- Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Questionnaires on HRQoL and sociodemographyOther
All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
| Study group | Role | What they receive |
|---|---|---|
| Australia | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Brazil | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| China | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Denmark | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Egypt | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Israel | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Lithuania | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| the Netherlands | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Portugal | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Russia | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| South Africa | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Spain | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Sweden | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| Turkey | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography | |
| the United Kingdom | Patients with a permanent colostomy after curative surgery for rectal cancer Receives: Other: Questionnaires on HRQoL and sociodemography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Validity of the Colostomy Impact Score
Description of sensitivity, specificity and construct validity (hypothesis testing) of the Colostomy Impact Score.
Measured: The end of 2018
Impact of demographic, socioeconomic and religious factors on HRQoL in rectal cancer survivors with a colostomy
Comparing HRQoL between sexes, age groups and different socioeconomic and religious groups and by country.
Measured: The end of 2018
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2018
- Study start1 Feb 2019
- Primary completion1 Dec 2019
- Study completion31 Dec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rectal NeoplasmsStudies of the same condition, open and under way.
- More trials run by Aarhus University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 3,750 participants (estimated)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Aarhus University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Eloy Espin, Department of Surgery, Universidad Autonoma de Barcelona, Kelly Buzatti, Federal University of Minas Gerais, Dong Pang, Peking University School of Nursing, Mansoura University, Edgar Furnee, University Medical Center, Groningen, Annika Sjövall, Karolinska Institute, Stockholm, Tomas Poskus, Faculty of Medicine, Vilnius University, Sheba Medical Center, Andrea Warwick, Redcliffe and QEII Jubilee Hospitals, Nuno Rama,Centro Hospitalar Leiria Pombal
- Responsible party
- Principal investigator, Helle Ø Kristensen, Aarhus University Hospital
- Investigators
- Helle Ø Kristensen, MD, Principal investigator, Danish Cancer Society Centre for Research on Survivorship and Late Adverse Effects After Cancer in the Pelvic Organs, Department of Surgery, Aarhus University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03516916
- Sponsor's protocol ID
- 490-98-0860
- Status last verified
- Nov 2020
- First submitted
- 24 Apr 2018
- Last updated
- 17 Nov 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surviving Rectal Cancer at the Cost of a Colostomy International Validation of the Colostomy Impact Score
- ClinicalTrials.gov ID
- NCT03516916
- Acronym / sponsor ID
- 490-98-0860
- Conditions
- Rectal Neoplasms, Quality of Life, Colostomy Stoma
- Keywords
- Rectal cancer, HRQoL, Stoma, Colostomy, Patient reported outcome measure (PROM)
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 3,750 participants (estimated)
- Lead sponsor
- Aarhus University HospitalUniversity, hospital or other
- Collaborators
- Eloy Espin, Department of Surgery, Universidad Autonoma de Barcelona, Kelly Buzatti, Federal University of Minas Gerais, Dong Pang, Peking University School of Nursing, Mansoura University, Edgar Furnee, University Medical Center, Groningen, Annika Sjövall, Karolinska Institute, Stockholm, Tomas Poskus, Faculty of Medicine, Vilnius University, Sheba Medical Center, Andrea Warwick, Redcliffe and QEII Jubilee Hospitals, Nuno Rama,Centro Hospitalar Leiria Pombal
- Study start
- 1 Feb 2019 (actual)
- Primary completion
- 1 Dec 2019 (actual)
- Study completion
- 31 Dec 2020 (estimated)
- First posted
- 7 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The formation of a colostomy following surgery for rectal cancer changes body image, challenges patient practical skills and threatens quality of life. As the oncological results have improved over the last decades the number of survivors from rectal cancer who have to adjust to a cancer free life in their own homes is increasing. To enable the identification of the patients with stoma-related reduced health-related Quality of life (HRQoL) in a quick and reliable way we recently developed the Colostomy Impact Score (CI-score) comprising 7 items of stoma related factors with significant impact on HRQoL. The purpose of the present project is to perform an international validation of the CI-score and to demonstrate its applicability.
The construct validity of the CI-score will be studied internationally on crosssectional cohorts of patients with permanent colostomy after abdominoperineal excision (APE) or Hartmann's procedure in Denmark, Sweden, Spain, the Netherlands, United Kingdom, Turkey, Brazil, Egypt, Russia, Lithuania, Israel, Portugal, South Africa, Australia and China. This will be done by testing the CI-score against five anchor questions stoma impact on HRQoL, the 5 Level version og the EuroQol measuer (EQ-5D-5L) and version 3.0 of the Quality of Life Questionnaire from the European Organisation for Research and Treatment of Cancer (EORTC QLQ C30 questionnaire v3.0).
The impact of the challenges related to having a stoma may vary with different demographic, socioeconomic and cultural factors. Supplementary data on stoma care, demographics and socioeconomic status will be gathered to study the impact of patient-related factors and cultural differences on HRQoL in rectal cancer survivors with an ostomy.
Detailed description
This retrospective cohort study has three main aims: 1) To identify demographic and socioeconomic factors influencing stoma impact and HRQoL, 2) To asses reliability and to validate the translated and cross-cultural adapted CI score internationally in multiple different centres, across a variety of patient groups and across cultural, religious, socioeconomic and physical borders and 3) To investigate if differences in everyday stoma care and -costs across countries and cultures affect CI or HRQoL.
International validation will be conducted as a retrospective cohort study on patients with a permanent colostomy after curative intended surgery more than 12 months prior to inclusion. Local health care professionals will identify includable patients and register relevant clinical information on each patient from the hospital chart. Most centres will include patients from national or regional databases, some will however include conveniently if a database is not available. Our international collaborators will be responsible for sending out and collecting the questionnaires and returning the completed questionnaires to the undersigned. In countries with sufficient internet accessibility and -infrastructure the data collection will be web based i.e. patients are sent a link to the redcap-database for them to enter their answers directly. Some centres will employ paper versions of the questionnaires. In areas with substantial number of illiterates investigator led interviews can be performed.
As the CI-score is a construct based on a formative model, statistical analysis based on the Classical Test Theory(CCT) and Item Response Theory (IRT) cannot be applied. However, the following aspects of validity and reliability from the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) checklist15-17 can and will be evaluated:
Content validity: Comprehensiveness and relevance of the questions in the CI-score have been ensured with the way of the development of the CI-score with the starting point in a Basic Stoma Questionnaire developed by an expert group supplemented by patients ensuring that all possible factors affecting stoma function/impact was included before regression analysis lead to the seven weighed questions1. After translation and cross-cultural adaptation face-validity of each translated CI-score will be assessed again by the collaborators before inclusion of patients.
Construct validity: This will be tested with hypothesis-testing. Hypotheses regarding mean differences and expected correlations between scores of instruments are formulated a priori. Hypotheses on how the CI-score and HRQoL are related to other factors are formulated a priori. For convergent validation the CI-score will be tested against 5 anchor questions (not validated) and the EORTC QLQ C30+ the colorectal specific CR29 (validated). Cross-cultural validity: See translation section.
Reliability: For a randomly selected subgroup in each country the CI-score and anchor question will be administered twice with an interval of approximately 2 weeks. The two administrations will be independent and both the setting when answering and the forms of administration will be similar for the individual patient. For ensuring stable patients an extra question on recent changes in stoma function will be added to the retest.
Translation of the CI-score will be managed by the lead institution with few exceptions (Turkey, Russia, Israel) and will follow the translation procedure recommended by the World Health Organization. All translations are produced by a forward-backward procedure. The latter procedure is performed to ensure, that the original meaning of the concepts is derived.
The original Danish version of the CI-score has already undergone a professional translation to English. A professional translation agency will perform the translation of the English version to languages in the included countries. All questionnaires/Case Report Forms (CRF) to be filled in by patients will undergo the same translation procedure as above.
A master version of the questionnaires will be collected into a booklet. On this basis, a RedCap database will be constructed to allow for direct electronic data entry by patients. Patient not able to access the web-based system, will fill in a paper version of the booklet. According to variation between populations in respect to practically illiterate's investigator lead data collection will be allowed. However, this should be agreed by the local investigation and the steering group in the planning of the data collection and included as individual amendment to the final protocol.
Data analysis:
Construct validity: Convergent validity will be studied by testing the CI-score on APE/Hartmann-patients against two measures of HRQoL; the anchor-questions assessing the overall stoma-impact on HRQoL, the EORTC QLQ C30 questionnaire version 3.0 and the EORTC QLQ CR29. Construct validity will furthermore be assessed by hypothesis-testing assessing the direction and magnitude of the expected correlations. Test-retest reliability will be studied on a subgroup in all included countries. Also, we will include questions on background demographics, socioeconomic status, everyday stoma care and -costs thereby enabling investigation of the practical and economic aspect of living with a stoma varying from country to country.
Statistical analysis:
Statistical analysis will be performed separately for each country. The correlations between total CI-score, anchor questions and the EORTC questionnaire results will be calculated for all participating patients according to the guidelines for the scores. For each CI-score group (minor CI/major CI) the mean EORTC QLQ C30-score will be calculated, testing the overall difference of impact on HRQoL between the CI-score groups.
Using the anchor-questions, the patients are divided into two HRQoL groups of those reporting no/minor or some/major impact on HRQoL. Relationship between CI-score and HRQoL group will be illustrated in box-plot for each country, where we expect statistically significant differences in median CI-score between the two HRQoL groups. Differences will be tested by Mann-Whitney U test. A contingency 2 by 2 table will be used to assess the degree of agreement between the two CI-score groups and the two HRQoL groups. Based on this, the sensitivity for the score will be calculated for each country. The added questions about irrigation and stoma-bag change frequency will be compared country-wise. Univariate regression analysis, descriptive analysis and estimation of impact on HRQoL will be performed. Test-retest reliability will be evaluated using Intraclass Correlation Coefficient and Cohens' Kappa.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Month
- Number of arms
- 15
| Arm | Type | Receives |
|---|---|---|
| Australia | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Brazil | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| China | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Denmark | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Egypt | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Israel | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Lithuania | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| the Netherlands | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Portugal | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Russia | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| South Africa | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Spain | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Sweden | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| Turkey | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
| the United Kingdom | – | Other: Questionnaires on HRQoL and sociodemographyPatients with a permanent colostomy after curative surgery for rectal cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients with a permanent colostomy after curative intended surgery for rectal cancer. Time since surgery must be more than 1 year. In some countries the cohort will be extracted from a national or institutional registry representing all operated patients in a certain time period that allows for inclusion of 250 patients. In countries whithout such registries convenient inclusion from the surgical department or stoma clinic.
Key inclusion criteria (2 listed)
- Curative intended Hartmann's procedure or abdominal perineal excision >12 months ago for carcinoma of the rectum
- Permanent colostomy
Key exclusion criteria (4 listed)
- Age < 18 years
- Recurrence of cancer
- Mental dementia
- Unable to understand the actual language
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Questionnaires on HRQoL and sociodemographyAll patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score. | Other | Australia, Brazil, China, Denmark, Egypt, Israel, Lithuania, Portugal, Russia, South Africa, Spain, Sweden, Turkey, the Netherlands, the United Kingdom |
Primary outcome
Validity of the Colostomy Impact Score
Time frame: The end of 2018
Description of sensitivity, specificity and construct validity (hypothesis testing) of the Colostomy Impact Score.
Impact of demographic, socioeconomic and religious factors on HRQoL in rectal cancer survivors with a colostomy
Time frame: The end of 2018
Comparing HRQoL between sexes, age groups and different socioeconomic and religious groups and by country.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2020.
- Individual participant dataSharing planned: No
Related trials for Rectal Neoplasms
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Helle Ø Kristensen, MD principal investigator
Danish Cancer Society Centre for Research on Survivorship and Late Adverse Effects After Cancer in the Pelvic Organs, Department of Surgery, Aarhus University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Rectal Neoplasms and Quality of Life, run by Aarhus University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Validity of the Colostomy Impact Score (time frame: The end of 2018). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2020.